Zobrazeno 1 - 10
of 130
pro vyhledávání: '"Michael A. Nauck"'
Autor:
Juris J. Meier, Daniel R. Quast, Michael A. Nauck, Nina Schenker, Carolyn F. Deacon, Jens J. Holst, Leona Plum‐Mörschel, Christoph Kapitza
Publikováno v:
Meier, J J, Quast, D R, Nauck, M A, Schenker, N, Deacon, C F, Holst, J J, Plum-Mörschel, L & Kapitza, C 2022, ' Acute effects of linagliptin on intact and total glucagon-like peptide-1 and gastric inhibitory polypeptide levels in insulin-dependent type 2 diabetes patients with and without moderate renal impairment ', Diabetes, Obesity and Metabolism, vol. 24, no. 5, pp. 806-815 . https://doi.org/10.1111/dom.14636
AIMS: To investigate the effect of renal impairment on incretin metabolism in patients with type 2 diabetes mellitus (T2DM) before and after treatment with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin.MATERIALS AND METHODS: Long-standing
Autor:
Michael A, Nauck, David A, D'Alessio
Publikováno v:
Cardiovascular Diabetology. 21
Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes in the USA, Europe, and the UAE. Tirzepatide is an acylated peptide engineered to activate the GIP and GLP-1 receptors, key mediators of insulin
Autor:
Richard N. Bergman, Takashi Kadowaki, Sonia M. Najjar, Timothy J. Kieffer, Jens J. Holst, Alan D. Cherrington, Michael A. Nauck, Jesse Roth, Frances M. Ashcroft, Helga Ellingsgaard, Barbara E. Corkey, Silvia Corvera, Michael P. Czech, Mark A. Atkinson, Oluf Pedersen, Alan R. Saltiel, Claes B. Wollheim, Roy Taylor
Publikováno v:
Cell Metabolism. 33:692-699
Marking insulin's centennial, we share stories of researchers and clinicians whose seminal work has advanced our understanding of insulin, islet biology, insulin resistance, and diabetes. The past century of pursuing the "hormone of hormones" and adv
Publikováno v:
Journal of Diabetes Research.
Background/Aim. We aimed to examine beneficial and adverse outcomes of basal insulin titration performed with different fasting plasma glucose (FPG) titration targets (TT). Methods. A PubMed literature search retrieved 43 reported prospective clinica
Publikováno v:
J Diabetes Sci Technol
Background: Pump-treated patients with type 1 diabetes have widely differing basal insulin infusion profiles. We analyzed consequences of such heterogeneity for glycemic control under fasting conditions. Methods: Data from 339 adult patients with typ
Publikováno v:
Experimental and Clinical Endocrinology & Diabetes. 130:77-84
Aim/Hypothesis It was the aim to prospectively study regimes of “preventive” carbohydrate administration to avoid major reduction in plasma glucose during physical activity. Methods 24 patients with type 1 diabetes (age 41±12 years; 11 women, 13
Autor:
Michael A. Nauck, Jessica A Marathe, Liza K. Phillips, Christopher K. Rayner, Chinmay S. Marathe, Tongzhi Wu, Hung Pham, Karen L. Jones, Laurence G. Trahair, Lian Huynh, Michael Horowitz
Publikováno v:
Acta Diabetologica. 57:583-587
Glucose-dependent insulinotropic polypeptide (GIP) is released primarily from the proximal small intestine and glucagon-like peptide-1 (GLP-1) from the more distal small intestine and colon. Their relative importance to the incretin effect in health
Autor:
Kerstin Stemmer, Stephen C. Woods, Harvey J. Grill, Jens J. Holst, Alessandro Pocai, Michael A. Nauck, Andreas Fritsche, Richard D. DiMarchi, David A. D'Alessio, Mads Tang-Christensen, Diego Perez-Tilve, Darleen A. Sandoval, Randy J. Seeley, Wolfgang Langhans, Daniel J. Drucker, Stephen R. Bloom, M.H. Tschöp, Brian Finan, Fiona M. Gribble, Timo D. Müller, Peter R. Flatt, Joel F. Habener, Juris J. Meier, Thue W. Schwartz, Frank Reimann
Publikováno v:
Molecular Metabolism, Vol 30, Iss, Pp 72-130 (2019)
Molecular Metabolism
Molecular Metabolism, 30
Mueller, T D, Finan, B, Bloom, S R, D'Alessio, D, Drucker, D J, Flatt, P R, Fritsche, A, Gribble, F, Grill, H J, Habener, J F, Holst, J J, Langhans, W, Meier, J J, Nauck, M A, Perez-Tilve, D, Pocai, A, Reimann, F, Sandoval, D A, Schwartz, T W, Seeley, R J, Stemmer, K, Tang-Christensen, M, Woods, S C, DiMarchi, R D & Tschoep, M H 2019, ' Glucagon-like peptide 1 (GLP-1) ', Molecular Metabolism, vol. 30, pp. 72-130 . https://doi.org/10.1016/j.molmet.2019.09.010
Molecular Metabolism
Molecular Metabolism, 30
Mueller, T D, Finan, B, Bloom, S R, D'Alessio, D, Drucker, D J, Flatt, P R, Fritsche, A, Gribble, F, Grill, H J, Habener, J F, Holst, J J, Langhans, W, Meier, J J, Nauck, M A, Perez-Tilve, D, Pocai, A, Reimann, F, Sandoval, D A, Schwartz, T W, Seeley, R J, Stemmer, K, Tang-Christensen, M, Woods, S C, DiMarchi, R D & Tschoep, M H 2019, ' Glucagon-like peptide 1 (GLP-1) ', Molecular Metabolism, vol. 30, pp. 72-130 . https://doi.org/10.1016/j.molmet.2019.09.010
Background: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, in
Publikováno v:
J Diabetes Sci Technol
Background: Twenty-four hour fasting periods are being used to scrutinize basal insulin infusion rates for pump-treated patients with type 1 diabetes. Methods: Data from 339 consecutive in-patients with adult type 1 diabetes on insulin pump therapy u
Publikováno v:
Diabetes, obesitymetabolismREFERENCES. 23
The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) have their main physiological role in augmenting insulin secretion after their nutrient-induced secretion from the gut. A functioning entero-